Tigilanol tiglate is under clinical development by QBiotics Group and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Tigilanol tiglate’s likelihood of approval (LoA) and phase transition for Melanoma took place on 18 May 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Tigilanol tiglate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Tigilanol tiglate overview

Tigilanol tiglate (EBC-46) is under development for the treatment of refractory cutaneous or subcutaneous tumors of squamous cell carcinoma of head and neck, malignant melanoma, squamous cell carcinoma of the skin and Merkel cell tumors of the skin, basal cell carcinoma, breast cancer, metastatic colorectal cancer, angiosarcoma, adenocarcinoma, fibrosarcoma, adenoid cystic sarcoma, atypical fibroxanthoma, salivary gland cancer, sino-nasal cancers and laryngeal cancer. It is administered through intratumoral route. The drug candidate is a tiglien-3-one derivative. It acts by targeting protein kinase C (PKC). The drug candidate is developed based on EcoLogic technology.

QBiotics Group overview

QBiotics Group discovers and develops plant-derived cell signalling molecules to treat diseases in humans and companion animals. The company is investigating tigilanol tiglate, a novel small molecule that is delivered into the tumor cells to treat head and neck squamous cell carcinoma, melanoma and soft tissue sarcoma; EBC-1013, a novel semi-synthetic small molecule topical gel to heal venous leg ulcer and burns; and antibiotics targeting multiple drug resistant bacteria. It is also developing therapies for canine soft tissue sarcoma, equine sarcoids and equine acute and chronic wounds in animals. The company utilizes its proprietary discovery platform EcoLogic, to develop drugs by anticipating cell signalling pathways in plant-environment, plant-animal and plant-microbe interactions. QBiotics Group is headquartered in Yungaburra, Queensland, Australia.

Quick View Tigilanol tiglate LOA Data

Report Segments
  • Innovator
Drug Name
  • Tigilanol tiglate
Administration Pathway
  • Intratumor
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.